1
|
Vilmun BM, Napolitano G, Lillholm M, Winkel RR, Lynge E, Nielsen M, Nielsen MB, Carlsen JF, von Euler-Chelpin M, Vejborg I. Introduction of one-view tomosynthesis in population-based mammography screening: Impact on detection rate, interval cancer rate and false-positive rate. J Med Screen 2024:9691413241262259. [PMID: 39053450 DOI: 10.1177/09691413241262259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2024]
Abstract
OBJECTIVE To assess performance endpoints of a combination of digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM) compared with FFDM only in breast cancer screening. MATERIALS AND METHODS This was a prospective population-based screening study, including eligible (50-69 years) women attending the Capital Region Mammography Screening Program in Denmark. All attending women were offered FFDM. A subgroup was consecutively allocated to a screening room with DBT. All FFDM and DBT underwent independent double reading, and all women were followed up for 2 years after screening date or until next screening date, whichever came first. RESULTS 6353 DBT + FFDM and 395 835 FFDM were included in the analysis and were undertaken in 196 267 women in the period from 1 November 2012 to 12 December 2018. Addition of DBT increased sensitivity: 89.9% (95% confidence interval (CI): 81.0-95.5) for DBT + FFDM and 70.1% (95% CI: 68.6-71.6) for FFDM only, p < 0.001. Specificity remained similar: 98.2% (95% CI: 97.9-98.5) for DBT + FFDM and 98.3% (95% CI: 98.2-98.3) for FFDM only, p = 0.9. Screen-detected cancer rate increased statistically significantly: 11.18/1000 for DBT + FFDM and 6.49/1000 for FFDM only, p < 0.001. False-positive rate was unchanged: 1.75% for DBT + FFDM and 1.73% for FFDM only, p = 0.9. Positive predictive value for recall was 39.0% (95% CI: 31.9-46.5) for DBT + FFDM and 27.3% (95% CI: 26.4-28.2), for FFDM only, p < 0.0005. The interval cancer rate decreased: 1.26/1000 for DBT + FFDM and 2.76/1000 for FFDM only, p = 0.02. CONCLUSION DBT + FFDM yielded a statistically significant increase in cancer detection and program sensitivity.
Collapse
Affiliation(s)
- Bolette Mikela Vilmun
- Department of Diagnostic Radiology, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Breast Examinations, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - George Napolitano
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Martin Lillholm
- Biomediq A/S, Dragør, Denmark
- Department of Computer Science, University of Copenhagen, Copenhagen, Denmark
| | - Rikke Rass Winkel
- Department of Diagnostic Radiology, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Radiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark
| | - Elsebeth Lynge
- Nykøbing Falster Hospital, University of Copenhagen, Nykøbing Falster, Denmark
| | - Mads Nielsen
- Biomediq A/S, Dragør, Denmark
- Department of Computer Science, University of Copenhagen, Copenhagen, Denmark
| | - Michael Bachmann Nielsen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Jonathan Frederik Carlsen
- Department of Diagnostic Radiology, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | | | - Ilse Vejborg
- Department of Diagnostic Radiology, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Breast Examinations, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark
| |
Collapse
|
2
|
Trentham-Dietz A, Chapman CH, Jayasekera J, Lowry KP, Heckman-Stoddard BM, Hampton JM, Caswell-Jin JL, Gangnon RE, Lu Y, Huang H, Stein S, Sun L, Gil Quessep EJ, Yang Y, Lu Y, Song J, Muñoz DF, Li Y, Kurian AW, Kerlikowske K, O'Meara ES, Sprague BL, Tosteson ANA, Feuer EJ, Berry D, Plevritis SK, Huang X, de Koning HJ, van Ravesteyn NT, Lee SJ, Alagoz O, Schechter CB, Stout NK, Miglioretti DL, Mandelblatt JS. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force. JAMA 2024; 331:1947-1960. [PMID: 38687505 DOI: 10.1001/jama.2023.24766] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
Abstract
Importance The effects of breast cancer incidence changes and advances in screening and treatment on outcomes of different screening strategies are not well known. Objective To estimate outcomes of various mammography screening strategies. Design, Setting, and Population Comparison of outcomes using 6 Cancer Intervention and Surveillance Modeling Network (CISNET) models and national data on breast cancer incidence, mammography performance, treatment effects, and other-cause mortality in US women without previous cancer diagnoses. Exposures Thirty-six screening strategies with varying start ages (40, 45, 50 years) and stop ages (74, 79 years) with digital mammography or digital breast tomosynthesis (DBT) annually, biennially, or a combination of intervals. Strategies were evaluated for all women and for Black women, assuming 100% screening adherence and "real-world" treatment. Main Outcomes and Measures Estimated lifetime benefits (breast cancer deaths averted, percent reduction in breast cancer mortality, life-years gained), harms (false-positive recalls, benign biopsies, overdiagnosis), and number of mammograms per 1000 women. Results Biennial screening with DBT starting at age 40, 45, or 50 years until age 74 years averted a median of 8.2, 7.5, or 6.7 breast cancer deaths per 1000 women screened, respectively, vs no screening. Biennial DBT screening at age 40 to 74 years (vs no screening) was associated with a 30.0% breast cancer mortality reduction, 1376 false-positive recalls, and 14 overdiagnosed cases per 1000 women screened. Digital mammography screening benefits were similar to those for DBT but had more false-positive recalls. Annual screening increased benefits but resulted in more false-positive recalls and overdiagnosed cases. Benefit-to-harm ratios of continuing screening until age 79 years were similar or superior to stopping at age 74. In all strategies, women with higher-than-average breast cancer risk, higher breast density, and lower comorbidity level experienced greater screening benefits than other groups. Annual screening of Black women from age 40 to 49 years with biennial screening thereafter reduced breast cancer mortality disparities while maintaining similar benefit-to-harm trade-offs as for all women. Conclusions This modeling analysis suggests that biennial mammography screening starting at age 40 years reduces breast cancer mortality and increases life-years gained per mammogram. More intensive screening for women with greater risk of breast cancer diagnosis or death can maintain similar benefit-to-harm trade-offs and reduce mortality disparities.
Collapse
Affiliation(s)
- Amy Trentham-Dietz
- Department of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison
| | - Christina Hunter Chapman
- Department of Radiation Oncology and Center for Innovations in Quality, Safety, and Effectiveness, Baylor College of Medicine, Houston, Texas
| | - Jinani Jayasekera
- Health Equity and Decision Sciences (HEADS) Research Laboratory, Division of Intramural Research at the National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, Maryland
| | | | - Brandy M Heckman-Stoddard
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - John M Hampton
- Department of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison
| | | | - Ronald E Gangnon
- Department of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison
- Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison
| | - Ying Lu
- Stanford University, Stanford, California
| | - Hui Huang
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Sarah Stein
- Harvard Pilgrim Health Care Institute, Boston, Massachusetts
| | - Liyang Sun
- Stanford University, Stanford, California
| | | | | | - Yifan Lu
- Department of Industrial and Systems Engineering and Carbone Cancer Center, University of Wisconsin-Madison
| | - Juhee Song
- University of Texas MD Anderson Cancer Center, Houston
| | | | - Yisheng Li
- University of Texas MD Anderson Cancer Center, Houston
| | - Allison W Kurian
- Departments of Medicine and Epidemiology and Population Health, Stanford University, Stanford, California
| | - Karla Kerlikowske
- Departments of Medicine and Epidemiology and Biostatistics, University of California San Francisco
| | - Ellen S O'Meara
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington
| | | | - Anna N A Tosteson
- Dartmouth Institute for Health Policy and Clinical Practice and Departments of Medicine and Community and Family Medicine, Dartmouth Geisel School of Medicine, Hanover, New Hampshire
| | - Eric J Feuer
- Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Donald Berry
- University of Texas MD Anderson Cancer Center, Houston
| | - Sylvia K Plevritis
- Departments of Biomedical Data Science and Radiology, Stanford University, Stanford, California
| | - Xuelin Huang
- University of Texas MD Anderson Cancer Center, Houston
| | | | | | - Sandra J Lee
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Oguzhan Alagoz
- Department of Industrial and Systems Engineering and Carbone Cancer Center, University of Wisconsin-Madison
| | | | - Natasha K Stout
- Harvard Pilgrim Health Care Institute, Boston, Massachusetts
- Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Diana L Miglioretti
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington
- Department of Public Health Sciences, University of California Davis
| | - Jeanne S Mandelblatt
- Departments of Oncology and Medicine, Georgetown University Medical Center, and Georgetown Lombardi Comprehensive Institute for Cancer and Aging Research at Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC
| |
Collapse
|
3
|
Osterhoff G, Rappert D, Scheyerer MJ, Disch AC, Ullrich BW, Spiegl UA, Schnake KJ. [Value of routine transpedicular biopsies in kyphoplasty and vertebroplasty for vertebral compression fractures : A survey among 250 spine surgeons]. UNFALLCHIRURGIE (HEIDELBERG, GERMANY) 2023; 126:873-879. [PMID: 35838762 PMCID: PMC10627954 DOI: 10.1007/s00113-022-01210-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/15/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Transpedicular cement augmentation is an established therapeutic option in the treatment of pathologic compression fractures of the spine. In addition to osteoporosis, underlying metastatic diseases or, more rarely, a primary bone tumor are recurrent causes of vertebral compression fractures without adequate trauma. OBJECTIVE To obtain a current opinion among spine surgeons in Germany, Switzerland, and Austria on the value of transpedicular biopsy during kyphoplasty and vertebroplasty of vertebral body fractures. MATERIAL AND METHODS A web-based (UmfrageOnline®) questionnaire with 11 questions was created and sent to the email distribution lists of the German Spine Society (DWG), the Austrian Society for Spine Surgery (spine.at), and the Swiss Society for Spinal Surgery (SGS), as well as to the email distribution list of the Spine Section of the German Society for Orthopedics and Trauma Surgery (DGOU). RESULTS Of a total of 2675 spine surgeons contacted 250 (9.3%) responded to the survey. Approximately one third (29.8%) of respondents regularly perform a transpedicular biopsy with each kyphoplasty or vertebroplasty. Reasons cited for biopsy were image morphology (79.7%) or history of suspected (66.0%) or present (71.4%) tumor disease. Reasons cited against routine biopsy were the associated costs and the limited informative value of the biopsies obtained. DISCUSSION Nearly one third of the spine surgeons surveyed regularly perform a transpedicular biopsy with each kyphoplasty or vertebroplasty. Almost all respondents perform biopsies at least when there is an imaging morphologic suspicion of tumor disease or tumor disease is known or suspected based on risk factors. Future studies need to further clarify the cost-effectiveness of transpedicular biopsy.
Collapse
Affiliation(s)
- Georg Osterhoff
- Klinik und Poliklinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Deutschland.
| | - Denis Rappert
- Interdisziplinäres Zentrum f. Wirbelsäulen- und Skoliosetherapie, Malteser Waldkrankenhaus St., Marien Rathsberger Str. 57, 91054, Erlangen, Deutschland
| | - Max J Scheyerer
- Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Kerpener Straße 62, 50937, Köln, Deutschland
| | - Alexander C Disch
- UniversitätsWirbelsäulenzentrum (UCSC), UniversitätsCentrum für Orthopädie, Unfall- & Plastische Chirurgie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fiedlerstraße 19, 01307, Dresden, Deutschland
| | - Bernhard W Ullrich
- Klinik für Unfall- und Wiederherstellungschirurgie, BG Klinikum Bergmannstrost GgmbH Halle, Merseburger Straße 165, 06112, Halle (Saale), Deutschland
- Klinik für Unfall‑, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Jena, Friedrich Schiller Universität Jena, 07747, Jena, Deutschland
| | - Ulrich A Spiegl
- Klinik und Poliklinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Deutschland
| | - Klaus J Schnake
- Interdisziplinäres Zentrum f. Wirbelsäulen- und Skoliosetherapie, Malteser Waldkrankenhaus St., Marien Rathsberger Str. 57, 91054, Erlangen, Deutschland
- Klinik für Orthopädie und Unfallchirurgie, Klinikum Nürnberg Süd, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Deutschland
| |
Collapse
|
4
|
Asl ER, Sarabandi S, Shademan B, Dalvandi K, sheikhansari G, Nourazarian A. MicroRNA targeting: A novel therapeutic intervention for ovarian cancer. Biochem Biophys Rep 2023; 35:101519. [PMID: 37521375 PMCID: PMC10382632 DOI: 10.1016/j.bbrep.2023.101519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 07/20/2023] [Accepted: 07/21/2023] [Indexed: 08/01/2023] Open
Abstract
Ovarian cancer, a perilous form of cancer affecting the female reproductive system, exhibits intricate communication networks that contribute to its progression. This study aims to identify crucial molecular abnormalities linked to the disease to enhance diagnostic and therapeutic strategies. In particular, we investigate the role of microRNAs (miRNAs) as diagnostic biomarkers and explore their potential in treating ovarian cancer. By targeting miRNAs, which can influence multiple pathways and genes, substantial therapeutic benefits can be attained. In this review we want to shed light on the promising application of miRNA-based interventions and provide insights into the specific miRNAs implicated in ovarian cancer pathogenesis.
Collapse
Affiliation(s)
- Elmira Roshani Asl
- Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran
| | - Sajed Sarabandi
- Department of Veterinary, Faculty of Medicine Sciences, Islamic Azad University of Karaj, Karaj, Iran
| | - Behrouz Shademan
- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Kourosh Dalvandi
- Ministry of Health and Medical Education, Health Department, Tehran, Iran
| | | | - Alireza Nourazarian
- Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran
| |
Collapse
|
5
|
Shademan B, Karamad V, Nourazarian A, Masjedi S, Isazadeh A, Sogutlu F, Avcı CB. MicroRNAs as Targets for Cancer Diagnosis: Interests and Limitations. Adv Pharm Bull 2023; 13:435-445. [PMID: 37646065 PMCID: PMC10460809 DOI: 10.34172/apb.2023.047] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 04/02/2022] [Accepted: 07/01/2022] [Indexed: 09/01/2023] Open
Abstract
MicroRNAs are small RNAs with ability to attach to the large number of RNA that regulate gene expression on post-transcriptional level via inhibition or degradation of specific mRNAs. MiRNAs in cells are the primary regulators of functions such as cell growth, differentiation, and apoptosis and considerably influence cell function. The expression levels of microRNAs change in human diseases, including cancer. These changes highlight their essential role in cancer pathogenesis. Ubiquitous irregular expression profiles of miRNAs have been detected in various human cancers using genome-wide identification techniques, which are emerging as novel diagnostic and prognostic cancer biomarkers of high specificity and sensitivity. The measurable miRNAs with enhanced stability in blood, tissues, and other body fluids provide a comprehensive source of miRNA-dependent biomarkers for human cancers. The leading role of miRNAs as potential biomarkers in human cancers is discussed in this article. In addition, the interests and difficulties of miRNAs as biomarkers have been explored.
Collapse
Affiliation(s)
- Behrouz Shademan
- Department of Medical Biology, Faculty of Medicine, EGE University, Izmir, Turkey
| | - Vahidreza Karamad
- Department of Medical Biology, Faculty of Medicine, EGE University, Izmir, Turkey
| | - Alireza Nourazarian
- Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran
| | - Sepideh Masjedi
- Department of Cellular and Molecular Biology Sciences, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran
| | - Alireza Isazadeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fatma Sogutlu
- Department of Medical Biology, Faculty of Medicine, EGE University, Izmir, Turkey
| | - Cigir Biray Avcı
- Department of Medical Biology, Faculty of Medicine, EGE University, Izmir, Turkey
| |
Collapse
|
6
|
La Forgia D, Signorile R, Bove S, Arezzo F, Cormio G, Daniele A, Dellino M, Fanizzi A, Gatta G, Lafranceschina M, Massafra R, Rizzo A, Zito FA, Neri E, Faggioni L. Impact of the systematic introduction of tomosynthesis on breast biopsies: 10 years of results. LA RADIOLOGIA MEDICA 2023:10.1007/s11547-023-01640-7. [PMID: 37198373 DOI: 10.1007/s11547-023-01640-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Accepted: 04/21/2023] [Indexed: 05/19/2023]
Abstract
Digital Breast Tomosynthesis (DBT) is a cutting-edge technology introduced in recent years as an in-depth analysis of breast cancer diagnostics. Compared with 2D Full-Field Digital Mammography, DBT has demonstrated greater sensitivity and specificity in detecting breast tumors. This work aims to quantitatively evaluate the impact of the systematic introduction of DBT in terms of Biopsy Rate and Positive Predictive Values for the number of biopsies performed (PPV-3). For this purpose, we collected 69,384 mammograms and 7894 biopsies, of which 6484 were Core Biopsies and 1410 were stereotactic Vacuum-assisted Breast Biopsies (VABBs), performed on female patients afferent to the Breast Unit of the Istituto Tumori "Giovanni Paolo II" of Bari from 2012 to 2021, thus, in the period before, during and after the systematic introduction of DBT. Linear regression analysis was then implemented to investigate how the Biopsy Rate had changed over the 10 year screening. The next step was to focus on VABBs, which were generally performed during in-depth examinations of mammogram detected lesions. Finally, three radiologists from the institute's Breast Unit underwent a comparative study to ascertain their performances in terms of breast cancer detection rates before and after the introduction of DBT. As a result, it was demonstrated that both the overall Biopsy Rate and the VABBs Biopsy Rate significantly decreased following the introduction of DBT, with the diagnosis of an equal number of tumors. Besides, no statistically significant differences were observed among the three operators evaluated. In conclusion, this work highlights how the systematic introduction of DBT has significantly impacted the breast cancer diagnostic procedure, by improving the diagnostic quality and thereby reducing needless biopsies, resulting in a consequent reduction in costs.
Collapse
Affiliation(s)
- Daniele La Forgia
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | - Rahel Signorile
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | - Samantha Bove
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | - Francesca Arezzo
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
- Department of Interdisciplinary Medicine (DIM), University of Bari Aldo Moro, 70121, Bari, Italy
| | - Gennaro Cormio
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
- Department of Interdisciplinary Medicine (DIM), University of Bari Aldo Moro, 70121, Bari, Italy
| | - Antonella Daniele
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | - Miriam Dellino
- Clinic of Obstetrics and Gynecology, San Paolo Hospital, 70123, Bari, Italy
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70100, Bari, Italy
| | - Annarita Fanizzi
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy.
| | - Gianluca Gatta
- Breast Unit, Department of Clinical and Experimental Internship, University of Campania Luigi Vanvitelli, Via De Crecchio 7, 80138, Naples, Italy
| | - Miria Lafranceschina
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | - Raffaella Massafra
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy.
| | - Alessandro Rizzo
- Istituto Tumori Giovanni Paolo II, I.R.C.C.S, Via Orazio Flacco 65, 70124, Bari, Italy
| | | | - Emanuele Neri
- Academic Radiology, Department of Translational Research, University of Pisa, Via Roma 67, 56126, Pisa, Italy
| | - Lorenzo Faggioni
- Academic Radiology, Department of Translational Research, University of Pisa, Via Roma 67, 56126, Pisa, Italy
| |
Collapse
|
7
|
Lee CS, Moy L. Lessons Learned from the Randomized Controlled TOmosynthesis plus SYnthesized MAmmography (TOSYMA) Trial. Radiology 2023; 306:e222178. [PMID: 36194117 PMCID: PMC9885334 DOI: 10.1148/radiol.222178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Revised: 09/06/2022] [Accepted: 09/09/2022] [Indexed: 01/26/2023]
Affiliation(s)
- Cindy S. Lee
- From the Department of Radiology, New York University School of
Medicine, 160 E 34th St, New York, NY 10016
| | - Linda Moy
- From the Department of Radiology, New York University School of
Medicine, 160 E 34th St, New York, NY 10016
| |
Collapse
|
8
|
Sekacheva M, Boroda A, Fatyanova A, Rozhkov A, Bagmet N. Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection. Front Oncol 2023; 13:1009863. [PMID: 37207139 PMCID: PMC10189101 DOI: 10.3389/fonc.2023.1009863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 04/17/2023] [Indexed: 05/21/2023] Open
Abstract
Background Without organized screening programs up to 60-70% of breast cancers are diagnosed at advanced stages that have significantly lower five-year survival rate and poorer outcomes, which is a serious global public health problem. The purpose of the blind clinical study was the assessment of the novel in-vitro diagnostic chemiluminescent CLIA-CA-62 assay for early-stage breast cancer detection. Methods Blind serum samples of 196 BC patients with known TNM staging, 85% with DCIS, Stage I & IIA, and 73 healthy control subjects were analyzed with the CLIA-CA-62 and CA 15-3 ELISA assays. Results were also compared to the pathology findings and to published data from mammography, MRI, ultrasound, and multi-cancer early detection test (MCED). Results The CLIA-CA-62 overall sensitivity for BC was 92% (100% for DCIS) at 93% specificity and it decreased in invasive stages (Stage I=97%, Stage II=85% and Stage III=83%). For the CA 15-3 assay sensitivity was 27-46% at 80% specificity. Sensitivity for mammography was 63-80% at 60% specificity, depending on the stage and the parenchymal density. Conclusion These results demonstrate that CLIA-CA-62 immunoassay could prove useful as a supplement to current mammography screening and other imaging methods, thus increasing the diagnostic sensitivity in DCIS and Stage I breast cancer detection.
Collapse
Affiliation(s)
- Marina Sekacheva
- World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia
- *Correspondence: Marina Sekacheva,
| | - Alexander Boroda
- World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Anastasia Fatyanova
- World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Alexander Rozhkov
- World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Nikolai Bagmet
- Department of Biliary, Hepatic, and Pancreatic Surgery, B.V. Petrovsky Russian Scientific Center of Surgery, Moscow, Russia
| |
Collapse
|
9
|
Balamou C, Koïvogui A, Zysman K, Rodrigue CM, Rymzhanova R. Impact of tomosynthesis on the evolution of the cancer detection rate in the French National Breast Cancer Screening Program. Public Health 2022; 210:65-73. [PMID: 35870323 DOI: 10.1016/j.puhe.2022.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 05/09/2022] [Accepted: 06/13/2022] [Indexed: 11/27/2022]
Abstract
OBJECTIVES This study aims to evaluate the cancer detection rate in French National Breast Cancer Screening Program, especially the cancer detection rate during second reading session (Reading 2) based on digital technologies used in radiology centres. STUDY DESIGN This was an analytical and descriptive study. METHODS Cancer detection rate was estimated by the ratio between the number of cancers detected and the number of women screened. The positive predictive value (PPV) was estimated as cancer detection rate among abnormal Reading 2. The relationship between Reading 2's PPV and the predictive factors was evaluated using multilevel mixed-effects logistic regression. RESULTS A total of 1,380,006 digital mammograms were retained in the analysis between 2010 and 2019. Cancer detection rate represented 7.8‰ at first reading session (Reading 1) and 0.5‰ at Reading 2. Cancer detection rate is significantly associated with the use of tomosynthesis (P < 0.001) at Reading 1, and differences appear within different tomosynthesis brands (P = 0.007). Reading 2's PPV differs significantly according on technologies used by first Reader (P < 0.004). Nevertheless, Reading 2 has 1.9 (1.5-2.4) more likely to predict a cancer with the presence of previous mammogram compared with those without previous images. CONCLUSION Using tomosynthesis technology improves cancer detection rate at Reading 1, even if differences are noticeable between brands. Using tomosynthesis technology at Reading 1 reduces Reading 2's PPV and cancer detection rate at Reading 2.
Collapse
Affiliation(s)
- C Balamou
- Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Site de L'Ain, 01000 Bourg-en-Bresse, France.
| | - A Koïvogui
- Centre Régional de Coordination des Dépistages des Cancers en Ile-de-France, Site de Seine-Saint-Denis, 93146 Bondy, France.
| | - K Zysman
- Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Site de L'Isère, 38240 Meylan, France.
| | - C M Rodrigue
- Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Site de L'Ain, 01000 Bourg-en-Bresse, France.
| | - R Rymzhanova
- Centre Régional de Coordination des Dépistages des Cancers en Bourgogne-Franche-Comté, Site Franche-Comté, 25000 Besançon, France
| |
Collapse
|
10
|
Thomassin-Naggara I, Ceugnart L, Tardivon A, Verzaux L, Balleyguier C, Taourel P, Seradour B. Intelligence artificielle : Place dans le dépistage du cancer du sein en France. Bull Cancer 2022; 109:780-785. [DOI: 10.1016/j.bulcan.2022.04.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 03/24/2022] [Accepted: 04/11/2022] [Indexed: 01/20/2023]
|
11
|
Kerlikowske K, Su YR, Sprague BL, Tosteson ANA, Buist DSM, Onega T, Henderson LM, Alsheik N, Bissell MCS, O’Meara ES, Lee CI, Miglioretti DL. Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer. JAMA 2022; 327:2220-2230. [PMID: 35699706 PMCID: PMC9198754 DOI: 10.1001/jama.2022.7672] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 04/21/2022] [Indexed: 12/15/2022]
Abstract
Importance Digital breast tomosynthesis (DBT) was developed with the expectation of improving cancer detection in women with dense breasts. Studies are needed to evaluate interval invasive and advanced breast cancer rates, intermediary outcomes related to breast cancer mortality, by breast density and breast cancer risk. Objective To evaluate whether DBT screening is associated with a lower likelihood of interval invasive cancer and advanced breast cancer compared with digital mammography by extent of breast density and breast cancer risk. Design, Setting, and Participants Cohort study of 504 427 women aged 40 to 79 years who underwent 1 003 900 screening digital mammography and 375 189 screening DBT examinations from 2011 through 2018 at 44 US Breast Cancer Surveillance Consortium (BCSC) facilities with follow-up for cancer diagnoses through 2019 by linkage to state or regional cancer registries. Exposures Breast Imaging Reporting and Data System (BI-RADS) breast density; BCSC 5-year breast cancer risk. Main Outcomes and Measures Rates per 1000 examinations of interval invasive cancer within 12 months of screening mammography and advanced breast cancer (prognostic pathologic stage II or higher) within 12 months of screening mammography, both estimated with inverse probability weighting. Results Among 504 427 women in the study population, the median age at time of mammography was 58 years (IQR, 50-65 years). Interval invasive cancer rates per 1000 examinations were not significantly different for DBT vs digital mammography (overall, 0.57 vs 0.61, respectively; difference, -0.04; 95% CI, -0.14 to 0.06; P = .43) or among all the 836 250 examinations with BCSC 5-year risk less than 1.67% (low to average-risk) or all the 413 061 examinations with BCSC 5-year risk of 1.67% or higher (high risk) across breast density categories. Advanced cancer rates were not significantly different for DBT vs digital mammography among women at low to average risk or at high risk with almost entirely fatty, scattered fibroglandular densities, or heterogeneously dense breasts. Advanced cancer rates per 1000 examinations were significantly lower for DBT vs digital mammography for the 3.6% of women with extremely dense breasts and at high risk of breast cancer (13 291 examinations in the DBT group and 31 300 in the digital mammography group; 0.27 vs 0.80 per 1000 examinations; difference, -0.53; 95% CI, -0.97 to -0.10) but not for women at low to average risk (10 611 examinations in the DBT group and 37 796 in the digital mammography group; 0.54 vs 0.42 per 1000 examinations; difference, 0.12; 95% CI, -0.09 to 0.32). Conclusions and Relevance Screening with DBT vs digital mammography was not associated with a significant difference in risk of interval invasive cancer and was associated with a significantly lower risk of advanced breast cancer among the 3.6% of women with extremely dense breasts and at high risk of breast cancer. No significant difference was observed in the 96.4% of women with nondense breasts, heterogeneously dense breasts, or with extremely dense breasts not at high risk.
Collapse
Affiliation(s)
- Karla Kerlikowske
- Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco
- General Internal Medicine Section, Department of Veterans Affairs, University of California, San Francisco
| | - Yu-Ru Su
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle
| | - Brian L. Sprague
- Departments of Surgery and Radiology, University of Vermont, Burlington
| | - Anna N. A. Tosteson
- The Dartmouth Institute for Health Policy and Clinical Practice and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
| | - Diana S. M. Buist
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle
| | - Tracy Onega
- Department of Population Health Sciences, University of Utah, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City, Utah
| | | | - Nila Alsheik
- School of Public Health, Division of Epidemiology and Biostatistics, University of Illinois at Chicago
| | | | - Ellen S. O’Meara
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle
| | | | - Diana L. Miglioretti
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle
- Department of Public Health Sciences, University of California, Davis
| |
Collapse
|
12
|
Heindel W, Weigel S, Gerß J, Hense HW, Sommer A, Krischke M, Kerschke L. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol 2022; 23:601-611. [PMID: 35427470 DOI: 10.1016/s1470-2045(22)00194-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/11/2022] [Accepted: 03/18/2022] [Indexed: 12/22/2022]
Abstract
BACKGROUND Two dimensional (2D) full-field digital mammography is the current standard of breast cancer screening. Digital breast tomosynthesis generates pseudo-three dimensional datasets of the breast from which synthesised 2D (s2D) mammograms can be reconstructed. This innovative approach reduces the likelihood of overlapping breast tissues that can conceal features of malignancy. We aimed to compare digital breast tomosynthesis plus s2D mammography with digital screening mammography for the detection of invasive breast cancer. METHODS TOSYMA was a randomised, open-label, superiority trial done at 17 screening units in two federal states of Germany. Eligible participants were women aged 50-69 years who had been invited to participate in a population-wide, quality-controlled mammography screening programme. Women were randomly assigned (1:1) to digital breast tomosynthesis plus s2D mammography or digital mammography alone using block randomisation (block size of 32), stratified by site. The primary endpoints were the detection rate of invasive breast cancer and invasive interval cancer rate at 24 months, analysed in the modified full analysis set, which included all randomly assigned participants who underwent either type of screening examination. Ten examinations, corresponding to a second study participation, were excluded. Analyses were done according to the intention-to-treat principle. Interval cancer rates will be reported in the follow-up study. Safety was assessed in the as-treated population, which included all participants who were randomly assigned. This trial is registered with ClinicalTrials.gov, NCT03377036, and is closed to accrual. FINDINGS Between July 5, 2018, and Dec 30, 2020, 99 689 women were randomly assigned to digital breast tomosynthesis plus s2D mammography (n=49 804) or digital mammography (n=49 830). Invasive breast cancers were detected in 354 of 49 715 women with evaluable primary endpoint data in the digital breast tomosynthesis plus s2D group (detection rate 7·1 cases per 1000 women screened) and in 240 of 49 762 women in the digital mammography group (4·8 cases per 1000 women screened; odds ratio 1·48 [95% CI 1·25-1·75]; p<0·0001). Adverse events and device deficiencies were rare (six adverse events in each group; 23 device deficiencies in the digital breast tomosynthesis plus s2D group vs five device deficiencies in the digital mammography group) and no serious adverse events were reported. INTERPRETATION The results from this study indicate that the detection rate for invasive breast cancer was significantly higher with digital breast tomosynthesis plus s2D mammography than digital mammography alone. Evaluation of interval cancer rates in the follow-up study will further help to investigate incremental long-term benefits of digital breast tomosynthesis screening. FUNDING Deutsche Forschungsgemeinschaft (German Research Foundation).
Collapse
Affiliation(s)
- Walter Heindel
- Clinic for Radiology and Reference Center for Mammography Münster, University of Münster and University Hospital Münster, Münster, Germany.
| | - Stefanie Weigel
- Clinic for Radiology and Reference Center for Mammography Münster, University of Münster and University Hospital Münster, Münster, Germany
| | - Joachim Gerß
- Institute of Biostatistics and Clinical Research, University of Münster and University Hospital Münster, Münster, Germany
| | - Hans-Werner Hense
- Institute of Epidemiology and Social Medicine, University of Münster and University Hospital Münster, Münster, Germany
| | - Alexander Sommer
- Clinic for Radiology and Reference Center for Mammography Münster, University of Münster and University Hospital Münster, Münster, Germany
| | - Miriam Krischke
- Centre for Clinical Trials Münster, University of Münster and University Hospital Münster, Münster, Germany
| | - Laura Kerschke
- Institute of Biostatistics and Clinical Research, University of Münster and University Hospital Münster, Münster, Germany
| |
Collapse
|
13
|
Heywang-Köbrunner Sylvia H, Alexander J, Astrid H, Sina W, Tobias V. Tomosynthesis with synthesised two-dimensional mammography yields higher cancer detection compared to digital mammography alone, also in dense breasts and in younger women: A Systematic Review and Meta-Analysis. Eur J Radiol 2022; 152:110324. [DOI: 10.1016/j.ejrad.2022.110324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 03/28/2022] [Accepted: 04/12/2022] [Indexed: 11/03/2022]
|
14
|
Mackenzie A, Thomson EL, Mitchell M, Elangovan P, van Ongeval C, Cockmartin L, Warren LM, Wilkinson LS, Wallis MG, Given-Wilson RM, Dance DR, Young KC. Virtual clinical trial to compare cancer detection using combinations of 2D mammography, digital breast tomosynthesis and synthetic 2D imaging. Eur Radiol 2022; 32:806-814. [PMID: 34331118 DOI: 10.1007/s00330-021-08197-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 06/07/2021] [Accepted: 07/01/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVES This study was designed to compare the detection of subtle lesions (calcification clusters or masses) when using the combination of digital breast tomosynthesis (DBT) and synthetic mammography (SM) with digital mammography (DM) alone or combined with DBT. METHODS A set of 166 cases without cancer was acquired on a DBT mammography system. Realistic subtle calcification clusters and masses in the DM images and DBT planes were digitally inserted into 104 of the acquired cases. Three study arms were created: DM alone, DM with DBT and SM with DBT. Five mammographic readers located the centre of any lesion within the images that should be recalled for further investigation and graded their suspiciousness. A JAFROC figure of merit (FoM) and lesion detection fraction (LDF) were calculated for each study arm. The visibility of the lesions in the DBT images was compared with SM and DM images. RESULTS For calcification clusters, there were no significant differences (p > 0.075) in FoM or LDF. For masses, the FoM and LDF were significantly improved in the arms using DBT compared to DM alone (p < 0.001). On average, both calcification clusters and masses were more visible on DBT than on DM and SM images. CONCLUSIONS This study demonstrated that masses were detected better with DBT than with DM alone and there was no significant difference (p = 0.075) in LDF between DM&DBT and SM&DBT for calcifications clusters. Our results support previous studies that it may be acceptable to not acquire digital mammography alongside tomosynthesis for subtle calcification clusters and ill-defined masses. KEY POINTS • The detection of masses was significantly better using DBT than with digital mammography alone. • The detection of calcification clusters was not significantly different between digital mammography and synthetic 2D images combined with tomosynthesis. • Our results support previous studies that it may be acceptable to not acquire digital mammography alongside tomosynthesis for subtle calcification clusters and ill-defined masses for the imaging technology used.
Collapse
Affiliation(s)
- Alistair Mackenzie
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK.
| | - Emma L Thomson
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Melissa Mitchell
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Premkumar Elangovan
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
| | | | - Lesley Cockmartin
- Department of Imaging and Pathology, Division of Medical Physics and Quality Assessment, KU Leuven, Herestraat 49, B-3000, Leuven, Belgium
| | - Lucy M Warren
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
| | - Louise S Wilkinson
- Oxford Breast Imaging Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Matthew G Wallis
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge & NIHR Cambridge Biomedical Research Centre, Cambridge, UK
| | | | - David R Dance
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Kenneth C Young
- National Coordinating Centre for the Physics in Mammography, Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| |
Collapse
|
15
|
Vasu D, Karthi Keyan A, Sakthinathan S, Chiu TW. Investigation of electrocatalytic and photocatalytic ability of Cu/Ni/TiO 2/MWCNTs Nanocomposites for detection and degradation of antibiotic drug Furaltadone. Sci Rep 2022; 12:886. [PMID: 35042930 PMCID: PMC8766570 DOI: 10.1038/s41598-022-04890-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 01/04/2022] [Indexed: 11/09/2022] Open
Abstract
In this manuscript, "Get two mangoes with one stone" strategy was used to study the electrochemical detection and photocatalytic mineralization of furaltadone (FLT) drug using Cu/Ni/TiO2/MWCNTs nanocomposites for the first time. The bi-functional nanocomposites were synthesized through a hydrothermal synthesis technique. The successfully synthesized nanocomposites were analyzed by various analytical techniques. The Cu/Ni/TiO2/MWCNTs nanocomposites decorated screen-printed carbon electrode (SPCE) exhibit a good electrocatalytic ability towards detection of FLT. Moreover, the electrocatalytic detection of FLT based on the nanocomposites decorated SPCE have high stability, lower detection limit, and excellent sensitivity of 0.0949 μM and 1.9288 μA μM-1 cm-2, respectively. In addition, the nanocomposites decorated SPCE electrodes performed in real samples, such as river water and tap water, the satisfactory results were observed. As UV-Visible spectroscopy revealed that the Cu/Ni/TiO2/MWCNTs nanocomposites had an excellent photocatalytic ability for degradation of FLT drug. The higher degradation efficiency of 75% was achieved within 45 min under irradiation of visible light. In addition, after the degradation process various intermediates are produced which is confirmed by GC-MS analysis. The excellent photocatalytic ability was improved to the dopant ions and restrictions of electron-hole pair.
Collapse
Affiliation(s)
- Dhanapal Vasu
- Department of Materials and Mineral Resources Engineering, National Taipei University of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taipei, Taiwan, ROC
| | - Arjunan Karthi Keyan
- Department of Materials and Mineral Resources Engineering, National Taipei University of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taipei, Taiwan, ROC
| | - Subramanian Sakthinathan
- Department of Materials and Mineral Resources Engineering, National Taipei University of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taipei, Taiwan, ROC.
| | - Te-Wei Chiu
- Department of Materials and Mineral Resources Engineering, National Taipei University of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taipei, Taiwan, ROC.
| |
Collapse
|
16
|
Screen-detected and interval breast cancer after concordant and discordant interpretations in a population based screening program using independent double reading. Eur Radiol 2022; 32:5974-5985. [PMID: 35364710 PMCID: PMC9381607 DOI: 10.1007/s00330-022-08711-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 03/02/2022] [Accepted: 03/04/2022] [Indexed: 01/19/2023]
Abstract
OBJECTIVES To analyze rates, odds ratios (OR), and characteristics of screen-detected and interval cancers after concordant and discordant initial interpretations and consensus in a population-based screening program. METHODS Data were extracted from the Cancer Registry of Norway for 487,118 women who participated in BreastScreen Norway, 2006-2017, with 2 years of follow-up. All mammograms were independently interpreted by two radiologists, using a score from 1 (negative) to 5 (high suspicion of cancer). A score of 2+ by one of the two radiologists was defined as discordant and 2+ by both radiologists as concordant positive. Consensus was performed on all discordant and concordant positive, with decisions of recall for further assessment or dismiss. OR was estimated with logistic regression with 95% confidence interval (CI), and histopathological tumor characteristics were analyzed for screen-detected and interval cancer. RESULTS Among screen-detected cancers, 23.0% (697/3024) had discordant scores, while 12.8% (117/911) of the interval cancers were dismissed at index screening. Adjusted OR was 2.4 (95% CI: 1.9-2.9) for interval cancer and 2.8 (95% CI: 2.5-3.2) for subsequent screen-detected cancer for women dismissed at consensus compared to women with concordant negative scores. We found 3.4% (4/117) of the interval cancers diagnosed after being dismissed to be DCIS, compared to 20.3% (12/59) of those with false-positive result after index screening. CONCLUSION Twenty-three percent of the screen-detected cancers was scored negative by one of the two radiologists. A higher odds of interval and subsequent screen-detected cancer was observed among women dismissed at consensus compared to concordant negative scores. Our findings indicate a benefit of personalized follow-up. KEY POINTS • In this study of 487,118 women participating in a screening program using independent double reading with consensus, 23% screen-detected cancers were detected by only one of the two radiologists. • The adjusted odds ratio for interval cancer was 2.4 (95% confidence interval: 1.9, 2.9) for cases dismissed at consensus using concordant negative interpretations as the reference. • Interval cancers diagnosed after being dismissed at consensus or after concordant negative scores had clinically less favorable prognostic tumor characteristics compared to those diagnosed after false-positive results.
Collapse
|
17
|
Mackenzie A, Kaur S, Thomson EL, Mitchell M, Elangovan P, Warren LM, Dance DR, Young KC. Effect of glandularity on the detection of simulated cancers in planar, tomosynthesis, and synthetic 2D imaging of the breast using a hybrid virtual clinical trial. Med Phys 2021; 48:6859-6868. [PMID: 34496038 DOI: 10.1002/mp.15216] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 07/19/2021] [Accepted: 08/26/2021] [Indexed: 12/15/2022] Open
Abstract
PURPOSE The purpose of this study was to measure the threshold diameter of calcifications and masses for 2D imaging, digital breast tomosynthesis (DBT), and synthetic 2D images, for a range of breast glandularities. This study shows the limits of detection for each of the technologies and the strengths and weaknesses of each in terms of visualizing the radiological features of small cancers. METHODS Mathematical voxel breast phantoms with glandularities by volume of 9%, 18%, and 30% with a thickness of 53 mm were created. Simulated ill-defined masses and calcification clusters with a range of diameters were inserted into some of these breast models. The imaging characteristics of a Siemens Inspiration X-ray system were measured for a 29 kV, tungsten/rhodium anode/filter combination. Ray tracing through the breast models was undertaken to create simulated 2D and DBT projection images. These were then modified to adjust the image sharpness, and to add scatter and noise. The mean glandular doses for the images were 1.43, 1.47, and 1.47 mGy for 2D and 1.92, 1.97, and 1.98 mGy for DBT for the three glandularities. The resultant images were processed to create 2D, DBT planes and synthetic 2D images. Patches of the images with or without a simulated lesion were extracted, and used in a four-alternative forced choice study to measure the threshold diameters for each imaging mode, lesion type, and glandularity. The study was undertaken by six physicists. RESULTS The threshold diameters of the lesions were 6.2, 4.9, and 6.7 mm (masses) and 225, 370, and 399 μm, (calcifications) for 2D, DBT, and synthetic 2D, respectively, for a breast glandularity of 18%. The threshold diameter of ill-defined masses is significantly smaller for DBT than for both 2D (p≤0.006) and synthetic 2D (p≤0.012) for all glandularities. Glandularity has a significant effect on the threshold diameter of masses, even for DBT where there is reduced background structure in the images. The calcification threshold diameters for 2D images were significantly smaller than for DBT and synthetic 2D for all glandularities. There were few significant differences for the threshold diameter of calcifications between glandularities, indicating that the background structure has little effect on the detection of calcifications. We measured larger but nonsignificant differences in the threshold diameters for synthetic 2D imaging than for 2D imaging for masses in the 9% (p = 0.059) and 18% (p = 0.19) glandularities. The threshold diameters for synthetic 2D imaging were larger than for 2D imaging for calcifications (p < 0.001) for all glandularities. CONCLUSIONS We have shown that glandularity has only a small effect on the detection of calcifications, but the threshold diameter of masses was significantly larger for higher glandularity for all of the modalities tested. We measured nonsignificantly larger threshold diameters for synthetic 2D imaging than for 2D imaging for masses at the 9% (p = 0.059) and 18% (p = 0.19) glandularities and significantly larger diameters for calcifications (p < 0.001) for all glandularities. The lesions simulated were very subtle and further work is required to examine the clinical effect of not seeing the smallest calcifications in clusters.
Collapse
Affiliation(s)
- Alistair Mackenzie
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
| | - Sukhmanjit Kaur
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Emma L Thomson
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Melissa Mitchell
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Premkumar Elangovan
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
| | - Lucy M Warren
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
| | - David R Dance
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| | - Kenneth C Young
- National Coordinating Centre for the Physics of Mammography (NCCPM), Royal Surrey NHS Foundation Trust, Guildford, UK
- Department of Physics, University of Surrey, Guildford, UK
| |
Collapse
|
18
|
Digital breast tomosynthesis (DBT) plus synthesised two-dimensional mammography (s2D) in breast cancer screening is associated with higher cancer detection and lower recalls compared to digital mammography (DM) alone: results of a systematic review and meta-analysis. Eur Radiol 2021; 32:2301-2312. [PMID: 34694451 PMCID: PMC8921114 DOI: 10.1007/s00330-021-08308-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 08/05/2021] [Accepted: 08/29/2021] [Indexed: 11/27/2022]
Abstract
Objectives Digital breast tomosynthesis (DBT) plus digital mammography (DM) in screening is problematic due to increased radiation by the double exposure. Synthesised two-dimensional mammography (s2D) calculated from DBT datasets at no additional dose appears a sensible alternative compared to adding DM. This systematic review and meta-analysis focuses on screening performance outcomes in women screened with DBT plus s2D compared to DM alone. Methods PubMed was searched from January 1, 2010, to September 2, 2020. Studies comparing DBT plus s2D to DM alone in breast cancer screening were included. Pooled risk ratios (RR) were estimated for cancer detection rates (CDR), recall rates, interval cancer rates (ICR), biopsy rates, and positive predictive values for recalls (PPV-1), for biopsies recommended (PPV-2), and for biopsies performed (PPV-3). Sensitivity analyses were performed using the leave-one-out approach. Risk of bias (RoB) was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Results Twelve papers covering 414,281 women were included from 766 records identified. CDR is increased ([RR, 95% CI] 1.35, 1.20–1.52), recall rates are decreased (0.79, 0.64–0.98), and PPV-1 is increased (1.69, 1.45–1.96) when using DBT plus s2D compared to DM alone. ICR and biopsy rates did not differ, but PPV-2 respectively PPV-3 increased with DBT plus s2D (1.57, 1.08–2.28 respectively 1.36, 1.17–1.58). Overall RoB of studies was assessed to be low. Conclusion Results show improved diagnostic outcomes with DBT plus s2D compared to DM alone and underline the value of DBT in combination with s2D in breast cancer screening. Key Points • DBT plus s2D is associated with higher CDR, lower recall rates, and a higher PPV-1 compared to DM alone in breast cancer screening. • No differences in biopsy rates were found between screening modalities, but PPV-2 and PPV-3 were higher in women screened with DBT plus s2D compared to DM alone. • We identified inconsistent results of ICR in two studies comparing DBT plus s2D to DM alone—resulting in no differences when pooling ICR in meta-analysis. Supplementary Information The online version contains supplementary material available at 10.1007/s00330-021-08308-8.
Collapse
|
19
|
Synthetic 2D Mammography Versus Standard 2D Digital Mammography: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2021; 217:314-325. [DOI: 10.2214/ajr.20.24204] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
20
|
Clauser P, Baltzer PAT, Kapetas P, Woitek R, Weber M, Leone F, Bernathova M, Helbich TH. One view or two views for wide-angle tomosynthesis with synthetic mammography in the assessment setting? Eur Radiol 2021; 32:661-670. [PMID: 34324025 PMCID: PMC8660729 DOI: 10.1007/s00330-021-08079-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 04/14/2021] [Accepted: 05/19/2021] [Indexed: 11/30/2022]
Abstract
Objectives To evaluate the diagnostic performance in the assessment setting of three protocols: one-view wide-angle digital breast tomosynthesis (WA-DBT) with synthetic mammography (SM), two-view WA-DBT/SM, and two-view digital mammography (DM). Methods Included in this retrospective study were patients who underwent bilateral two-view DM and WA-DBT. SM were reconstructed from the WA-DBT data. The standard of reference was histology and/or 2 years follow-up. Included were 205 women with 179 lesions (89 malignant, 90 benign). Four blinded readers randomly evaluated images to assess density, lesion type, and level of suspicion according to BI-RADS. Three protocols were evaluated: two-view DM, one-view (mediolateral oblique) WA-DBT/SM, and two-view WA-DBT/SM. Detection rate, sensitivity, specificity, and accuracy were calculated and compared using multivariate analysis. Reading time was assessed. Results The detection rate was higher with two-view WA-DBT/SM (p = 0.063). Sensitivity was higher for two-view WA-DBT/SM compared to two-view DM (p = 0.001) and one-view WA-DBT/SM (p = 0.058). No significant differences in specificity were found. Accuracy was higher with both one-view WA-DBT/SM and two-view WA-DBT/SM compared to DM (p = 0.003 and > 0.001, respectively). Accuracy did not differ between one- and two-view WA-DBT/SM. Two-view WA-DBT/SM performed better for masses and asymmetries. Reading times were significantly longer when WA-DBT was evaluated. Conclusions One-view and two-view WA-DBT/SM can achieve a higher diagnostic performance compared to two-view DM. The detection rate and sensitivity were highest with two-view WA-DBT/SM. Two-view WA-DBT/SM appears to be the most appropriate tool for the assessment of breast lesions. Key Points • Detection rate with two-view wide-angle digital breast tomosynthesis (WA-DBT) is significantly higher than with two-view digital mammography in the assessment setting. • Diagnostic accuracy of one-view and two-view WA-DBT with synthetic mammography (SM) in the assessment setting is higher than that of two-view digital mammography. • Compared to one-view WA-DBT with SM, two-view WA-DBT with SM seems to be the most appropriate tool for the assessment of breast lesions.
Collapse
Affiliation(s)
- Paola Clauser
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria.
| | - Pascal A T Baltzer
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria
| | - Panagiotis Kapetas
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria
| | - Ramona Woitek
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria
| | - Michael Weber
- Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Federica Leone
- Ospedale Luigi Sacco - Polo Universitario, via G.B. Grassi 74, 20157, Milan, Italy
| | - Maria Bernathova
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria
| | - Thomas H Helbich
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna/General Hospital Vienna, Waehringer Guertel 18-20, Vienna, Austria
| |
Collapse
|
21
|
Zeng B, Yu K, Gao L, Zeng X, Zhou Q. Breast cancer screening using synthesized two-dimensional mammography: A systematic review and meta-analysis. Breast 2021; 59:270-278. [PMID: 34329948 PMCID: PMC8333340 DOI: 10.1016/j.breast.2021.07.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 07/19/2021] [Accepted: 07/20/2021] [Indexed: 11/25/2022] Open
Abstract
Purpose We conducted a systematic review and meta-analysis to compare the screening performance of synthesized mammography (SM) plus digital breast tomosynthesis (DBT) with digital mammography (DM) plus DBT or DM alone. Methods Medline, Embase, Web of Science, and the Cochrane Library databases were searched from January 2010 to January 2021. Eligible population-based studies on breast cancer screening comparing SM/DBT with DM/DBT or DM in asymptomatic women were included. A random-effect model was used in this meta-analysis. Data were summarized as risk differences (RDs), with 95 % confidence intervals (CIs). Results Thirteen studies involving 1,370,670 participants were included. Compared with DM/DBT, screening using SM/DBT had similar breast cancer detection rate (CDR) (RD = −0.1/1000 screens, 95 % CI = −0.4 to 0.2, p = 0.557, I2 = 0 %), but lower recall rate (RD = −0.56 %, 95 % CI = −1.03 to −0.08, p = 0.022, I2 = 90 %) and lower biopsy rate (RD = −0.33 %, 95 % CI = −0.56 to −0.10, p = 0.005, I2 = 78 %). Compared with DM, SM/DBT improved CDR (RD = 2.0/1000 screens, 95 % CI = 1.4 to 2.6, p < 0.001, I2 = 63 %) and reduced recall rate (RD = −0.95 %, 95 % CI = −1.91 to −0.002, p = 0.049, I2 = 99 %). However, SM/DBT and DM had similar interval cancer rate (ICR) (RD = 0.1/1000 screens, 95 % CI = −0.6 to 0.8, p = 0.836, I2 = 71 %) and biopsy rate (RD = −0.05 %, 95 % CI = −0.35 to 0.24, p = 0.727, I2 = 93 %). Conclusions Screening using SM/DBT has similar breast cancer detection but reduces recall and biopsy when compared with DM/DBT. SM/DBT improves CDR when compared with DM, but they have little difference in ICR. SM/DBT could replace DM/DBT in breast cancer screening to reduce radiation dose. Screening using SM/DBT has similar breast cancer detection but reduces recall and biopsy when compared with DM/DBT. Screening using SM/DBT improves cancer detection rate when compared with DM/DBT alone. There was no significant difference in interval cancer rate between SM/DBT and DM. SM/DBT could replace DM/DBT in breast cancer screening to reduce radiation dose.
Collapse
Affiliation(s)
- Baoqi Zeng
- Department of Science and Education, Peking University Binhai Hospital, Tianjin, China.
| | - Kai Yu
- Department of Science and Education, Peking University Binhai Hospital, Tianjin, China
| | - Le Gao
- Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China
| | - Xueyang Zeng
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China
| | - Qingxin Zhou
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China
| |
Collapse
|
22
|
Pang JX, Newsome J, Sun M, Chiang B, Mutti-Packer S, McDonald SW, Yang H. Impact of switching from digital mammography to tomosynthesis plus digital mammography on breast cancer screening in Alberta, Canada. J Med Screen 2021; 29:38-43. [PMID: 34266324 DOI: 10.1177/09691413211032265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To compare abnormal call rates (ACR), cancer detection rates (CDR), positive predictive values (PPVs), and annual return to screen recommendations after switching from digital mammography (DM) to digital breast tomosynthesis plus DM (DBT + DM) for breast cancer screening. SETTING The Alberta Breast Cancer Screening Program collects screening data from clinics throughout the province of Alberta, Canada. METHODS This study retrospectively collected data, between 2015 and 2018, on women aged 40+ who underwent breast cancer screening at two large volume multisite radiology groups to compare metrics one year prior and one year after DBT + DM implementation. Comparisons between modalities were carried out within age groups, within breast density categories, and for initial vs. subsequent screens. RESULTS A total of 125,432 DM and 128,912 DBT + DM screening exams were performed. For women aged 50-74, the DBT + DM group had a higher ACR (p < 0.01) but lower annual return to screens (p < 0.01). CDR was higher post-DBT + DM implementation for women with scattered (6.0 per 1000 vs. 4.4 per 1000; p = 0.001) or heterogeneously dense breasts (6.5 per 1000 vs. 4.2 per 1000; p < 0.001). PPV was higher with DBT + DM for all age groups, with women 50-74 having a PPV of 8.3% using DBT + DM vs. 7.1% with DM (p = 0.009). CONCLUSION All metrics improved or stayed the same after switching to DBT + DM except for ACR. However, the increase in ACR could be attributed to a trend already occurring prior to the switch. Longer term monitoring is needed to confirm these findings.
Collapse
Affiliation(s)
- Jack Xq Pang
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| | - James Newsome
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| | - Maggie Sun
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| | - Bonnie Chiang
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| | - Seema Mutti-Packer
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| | - Sheila W McDonald
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Huiming Yang
- Department of Provincial Population and Public Health, Alberta Health Services, Edmonton, Alberta, Canada
| |
Collapse
|
23
|
Houssami N, Hofvind S, Soerensen AL, Robledo KP, Hunter K, Bernardi D, Lång K, Johnson K, Aglen CF, Zackrisson S. Interval breast cancer rates for digital breast tomosynthesis versus digital mammography population screening: An individual participant data meta-analysis. EClinicalMedicine 2021; 34:100804. [PMID: 33997729 PMCID: PMC8102709 DOI: 10.1016/j.eclinm.2021.100804] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/02/2021] [Accepted: 03/03/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Digital breast tomosynthesis (DBT) improves breast cancer (BC) detection compared to mammography, however, it is unknown whether this reduces interval cancer rate (ICR) at follow-up. METHODS Using individual participant data (IPD) from DBT screening studies (identified via periodic literature searches July 2016 to November 2019) we performed an IPD meta-analysis. We estimated ICR for DBT-screened participants and the difference in pooled ICR for DBT and mammography-only screening, and compared interval BC characteristics. Two-stage meta-analysis (study-specific estimation, pooled synthesis) of ICR included random-effects, adjusting for study and age, and was estimated in age and density subgroups. Comparative screening sensitivity was calculated using screen-detected and interval BC data. FINDINGS Four prospective DBT studies, from European population-based programs, contributed IPD for 66,451 DBT-screened participants: age-adjusted pooled ICR was 13.17/10,000 (95%CI: 8.25-21.02). Pooled ICR was higher in the high-density (21.08/10,000; 95%CI: 6.71-66.27) than the low-density (8.63/10,000; 95%CI: 5.25-14.192) groups (P = 0.03) however estimates did not differ across age-groups (P = 0.32). Based on two studies that also provided data for 153,800 mammography screens (age-adjusted ICR 17.69/10,000; 95%CI: 13.22-23.66), DBT's pooled ICR was 16.83/10,000 (95%CI: 11.89-23.82). Comparative meta-analysis showed a non-significant difference in ICR (-0.44/10,000; 95%CI: -11.00-10.11) and non-significant difference in screening sensitivity (6.79%; 95%CI: -0.73-14.87%) between DBT and DM but a significant pooled difference in cancer detection rate of 33.49/10,000 (95%CI: 23.88-43.10). Distribution of interval BC prognostic characteristics did not differ between screening modalities except that those occurring in DBT-screened participants were significantly more likely to be negative for axillary-node metastases (P = 0.005). INTERPRETATION Although heterogeneity in ICR estimates and few datasets limit recommendations, there was no difference between DBT and mammography in pooled ICR despite DBT increasing cancer detection.
Collapse
Affiliation(s)
- Nehmat Houssami
- Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- Corresponding author.
| | - Solveig Hofvind
- Section of Breast Screening, Cancer Registry of Norway, Oslo, Norway
| | - Anne L. Soerensen
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - Kristy P. Robledo
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - Kylie Hunter
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - Daniela Bernardi
- Breast Imaging and Screening Unit, Department of Radiology, Humanitas Research Hospital, Milan, Italy
| | - Kristina Lång
- Department of Translational Medicine, Diagnostic Radiology, Lund University, Skane University Hospital, Malmö, Sweden
| | - Kristin Johnson
- Department of Translational Medicine, Diagnostic Radiology, Lund University, Skane University Hospital, Malmö, Sweden
| | - Camilla F. Aglen
- Section of Breast Screening, Cancer Registry of Norway, Oslo, Norway
| | - Sophia Zackrisson
- Department of Translational Medicine, Diagnostic Radiology, Lund University, Skane University Hospital, Malmö, Sweden
| |
Collapse
|
24
|
Heindel W, Bock K, Hecht G, Heywang-Köbrunner S, Kääb-Sanyal V, Siegmann-Luz K, Weigel S. [Systematic and quality-assured early diagnosis of sporadic breast cancer : Update on screening effects and scientific studies]. Radiologe 2021; 61:126-136. [PMID: 33492420 PMCID: PMC7851039 DOI: 10.1007/s00117-020-00803-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/21/2020] [Indexed: 12/05/2022]
Abstract
BACKGROUND A quality-assured mammography screening programme has been available since 2009, nationwide, to all women in Germany between the ages of 50 and 69. The programme is based on the European Guidelines. In this review article the authors summarize the current status of scientific assessments of this national early detection programme for breast cancer and provide an outlook regarding ongoing studies on effectiveness tests and further development. RESULTS We expect a decline in mortality rates relating to breast cancer as a result of successfully bringing diagnoses forward and a decrease in advanced breast cancer after a repeated screening. The extent will be shown in the current ZEBra study on mortality evaluation. CONCLUSION Potential for a further increase in the effectiveness of the systematic early detection of breast cancer can be identified in four areas: (1) More women should take advantage of the early detection opportunities offered by the medical insurance funds; so far, on average, only about 50% of the women between 50 and 69 who are entitled to a screening examination actually take part in the programme. (2) Entitlement to take part in the programme should be extended to women over 70. (3) The further development of digital mammography towards digital breast tomosynthesis promises to reduce the number of false positive recalls while at the same time increasing sensitivity. (4) There should be scientific studies relating to an extension of screening strategies for the small number of women in the entitlement range who have extremly dense breasts.
Collapse
Affiliation(s)
- Walter Heindel
- Klinik für Radiologie und Referenzzentrum Mammographie Münster, Universität Münster (WWU) und Universitätsklinikum Münster (UKM), Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland.
| | - Karin Bock
- Referenzzentrum Mammographie Südwest, Bahnhofstraße 7, 35037, Marburg, Deutschland
| | - Gerold Hecht
- Referenzzentrum Mammographie Nord, Heiligengeiststraße 28, 26121, Oldenburg, Deutschland
| | | | - Vanessa Kääb-Sanyal
- Geschäftsstelle der Kooperationsgemeinschaft Mammographie, Goethestraße 85, 10623, Berlin, Deutschland
| | - Katja Siegmann-Luz
- Referenzzentrum Mammographie Berlin, Straße des 17. Juni 106-108, 10623, Berlin, Deutschland
| | - Stefanie Weigel
- Klinik für Radiologie und Referenzzentrum Mammographie Münster, Universität Münster (WWU) und Universitätsklinikum Münster (UKM), Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland
| |
Collapse
|